Diisopropylethylamine → 3-[1-({4-[(4aR,10bR)-9-ethoxy-8-methoxy-3,4,4a,10b-tetrahydro-1H-thiopyrano[4,3-c]isoquinolin-6-yl]phenyl}carbonyl)piperidin-4-yl]-1-{[2-(methoxymethyl)-2H-tetrazol-5-yl]methyl}-6-phenylthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione

HRID 1476539노트

반응식

HRID 1476539 반응식
C([O:3][C:4]1[C:13]([O:14][CH3:15])=[CH:12][C:11]2[C:10](C3C=CC(C(O)=O)=CC=3)=[N:9][C@@H:8]3[CH2:25][CH2:26][S:27][CH2:28][C@@H:7]3[C:6]=2[CH:5]=1)C.[B-](F)(F)(F)F.CCO[C:37]([C:39]([C:49]#N)=NOC(N(C)C)=[N+](C)C)=[O:38].[CH:51]1C=N[C:54]2N(O)N=N[C:53]=2[CH:52]=1.[CH3:61][CH2:62]N(C(C)C)C(C)C.FC(F)(F)C(O)=O.[CH3:77][O:78][CH2:79][N:80]1[N:84]=[N:83][C:82]([CH2:85][N:86]2[C:91]3[CH:92]=[C:93]([C:95]4[CH:100]=[CH:99][CH:98]=[CH:97][CH:96]=4)[S:94][C:90]=3[C:89](=[O:101])[N:88]([CH:102]3[CH2:107][CH2:106][NH:105][CH2:104][CH2:103]3)[C:87]2=[O:108])=[N:81]1>C(Cl)Cl>[CH2:61]([O:3][C:4]1[C:13]([O:14][CH3:15])=[CH:12][C:11]2[C:10]([C:52]3[CH:51]=[CH:49][C:39]([C:37]([N:105]4[CH2:106][CH2:107][CH:102]([N:88]5[C:89](=[O:101])[C:90]6[S:94][C:93]([C:95]7[CH:100]=[CH:99][CH:98]=[CH:97][CH:96]=7)=[CH:92][C:91]=6[N:86]([CH2:85][C:82]6[N:83]=[N:84][N:80]([CH2:79][O:78][CH3:77])[N:81]=6)[C:87]5=[O:108])[CH2:103][CH2:104]4)=[O:38])=[CH:54][CH:53]=3)=[N:9][C@@H:8]3[CH2:7][CH2:28][S:27][CH2:26][C@@H:25]3[C:6]=2[CH:5]=1)[CH3:62]

참가 물질

7

반응물 5

HCID 81531DiisopropylethylamineHCID 181649HOAt2회HCID 2733286O-[(Ethoxycarbonyl)cyanomethylenamino]-N,N,N',N'-tetramethyluronium tetrafluoroborate2회HCID 67258448HCID 67258448, 화합물HCID 672590924-[(4aR,10bR)-9-ethoxy-8-methoxy-3,4,4a,10b-tetrahydro-1H-thiopyrano[4,3-c]isoquinolin-6-yl]benzoic acid2회

생성물 1

HCID 532471203-[1-({4-[(4aR,10bR)-9-ethoxy-8-methoxy-3,4,4a,10b-tetrahydro-1H-thiopyrano[4,3-c]isoquinolin-6-yl]phenyl}carbonyl)piperidin-4-yl]-1-{[2-(methoxymethyl)-2H-tetrazol-5-yl]methyl}-6-phenylthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione

시약·촉매·용매 1

HCID 6344Dichloromethane용매

실험 절차

A mixture of 4-[(4aR,10bR)-9-ethoxy-8-methoxy-3,4,4a,10b-tetrahydro-1H-thiopyrano[4,3-c]isoquinolin-6-yl]benzoic acid (251 mg; compound C10), TOTU (270 mg), HOAT (129 mg), DIPEA (327 mg) in DCM (8 ml) is stirred for 1 h at RT. To this mixture 1-{[2-(methoxymethyl)-2H-tetrazol-5-yl]methyl}-6-phenyl-3-(piperidin-4-yl)thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione trifluoroacetate (359 mg; compound B25) is added and the reaction mixture is stirred for additional 3 h at RT. Additional 4-[(4aR,10bR)-9-ethoxy-8-methoxy-3,4,4a,10b-tetrahydro-1H-thiopyrano[4,3-c]isoquinolin-6-yl]benzoic acid (125 mg; compound C10), TOTU (207 mg) and HOAT (86 mg) are added to drive the reaction to completion. After stirring for 1 h at RT the reaction is quenched by addition of DCM (10 ml) and a saturated aqueous solution of sodium bicarbonate (10 ml). The organic phase is separated and the aqueous phase is extracted with DCM (5 ml). The combined organic phases are applied to a phase separator and the solvent is removed under vacuum. The resulting residue is purified by flash column chromatography [amino phase silica gel, eluation gradient: cyclohexane/EtOAc, 100/0 to 0/100 (v/v)] to yield the title compound as a solid.

후처리

  1. stirringthe reaction mixture is stirred for additional 3 h at RT
  2. customthe reaction to completion
  3. stirringAfter stirring for 1 h at RT the reaction
  4. customis quenched by addition of DCM (10 ml)
  5. customThe organic phase is separated
  6. extractionthe aqueous phase is extracted with DCM (5 ml)
  7. customthe solvent is removed under vacuum
  8. customThe resulting residue is purified by flash column chromatography [amino phase silica gel, eluation gradient: cyclohexane/EtOAc, 100/0 to 0/100 (v/v)]

출처 및 근거

ORD 기록
ord-fcd38bdffba6414b868275e818fe30ef
출처 데이터셋
uspto-grants-2015_04
특허 번호
US09018175B2

반응 노트

불러오는 중…